Targeting deregulated epigenetic control in cancer
Article first published online: 25 JUL 2013
Copyright © 2013 Wiley Periodicals, Inc.
Journal of Cellular Physiology
Volume 228, Issue 11, pages 2103–2108, November 2013
How to Cite
Zaidi, S. K., Van Wijnen, A. J., Lian, J. B., Stein, J. L. and Stein, G. S. (2013), Targeting deregulated epigenetic control in cancer. J. Cell. Physiol., 228: 2103–2108. doi: 10.1002/jcp.24387
- Issue published online: 25 JUL 2013
- Article first published online: 25 JUL 2013
- Accepted manuscript online: 15 APR 2013 06:52AM EST
- Manuscript Received: 2 APR 2013
- Manuscript Accepted: 2 APR 2013
- National Institutes of Health. Grant Number: P01 CA082834
- National Cancer Institute/Wistar Institute. Grant Number: P01 CA140043
- Pfizer Pharmaceuticals. Grant Number: WS2049100
Cancer is a multifaceted disease that involves acquisition of genetic mutations, deletions, and amplifications as well as deregulation of epigenetic mechanisms that fine-tune gene regulation. Key epigenetic mechanisms that include histone modifications, DNA methylation, and non-coding RNA-mediated gene silencing are often deregulated in a variety of cancers. Subnuclear localization of key proteins in the interphase nucleus and bookmarking of genes by lineage commitment factors in mitosis—a new dimension to epigenetic control of fundamental biological processes—is also modified in cancer. In this review, we discuss the various aspects of epigenetic control that are operative in a variety of cancers and their potential for risk assessment, early detection, targeted therapy, and personalized medicine. J. Cell. Physiol. 228: 2103–2108, 2013. © 2013 Wiley Periodicals, Inc.